Who are miltefosine + Paromomycin sulfate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Miltefosine and Paromomycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/miltefosine-paromomycin-sulfate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

miltefosine + Paromomycin sulfate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

miltefosine + Paromomycin sulfate (miltefosine + Paromomycin sulfate) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiparasitic combination therapy. Area: Infectious Disease / Parasitology.

phase 3 Antiparasitic combination therapy Leishmania cell membrane and ribosomal protein synthesis Infectious Disease / Parasitology Small molecule Live · refreshed every 30 min

Target snapshot

miltefosine + Paromomycin sulfate (miltefosine + Paromomycin sulfate) — Banaras Hindu University. Miltefosine disrupts parasite cell membranes while paromomycin inhibits protein synthesis, together providing synergistic activity against Leishmania parasites.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
miltefosine + Paromomycin sulfate TARGET	miltefosine + Paromomycin sulfate	Banaras Hindu University	phase 3	Antiparasitic combination therapy	Leishmania cell membrane and ribosomal protein synthesis
Miltefosine and Paromomycin	Miltefosine and Paromomycin	Drugs for Neglected Diseases	phase 3	Antiparasitic combination	Leishmania cell membrane and ribosomal protein synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiparasitic combination therapy class)

Banaras Hindu University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). miltefosine + Paromomycin sulfate — Competitive Intelligence Brief. https://druglandscape.com/ci/miltefosine-paromomycin-sulfate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab